Chinese Vape Makers Face Regulatory Heat Amid Dominance in German Market UK Government Announces 120m Support Package for Ceramics Industry Tax Season 2025 New Rules May Help Online Sellers and EV Buyers Save Singamas Shares Slide After US DOJ Alleges CEO Teo Siong Seng Involved in PriceFixing Conspiracy Nvidia Stock Analysis AI Giants Earnings Report Fuels Investor Optimism Ofcom Flags Child Safety Concerns on TikTok and YouTube Regulatory Risks Loom for Tech Giants AIT Q1 2026 Earnings EPS Misses Estimates by a Slim Margin Stock Edges Higher USLM Q1 2026 Earnings EPS Misses Estimates as Stock Edges Higher DLHC Q1 2026 Earnings EPS Misses Estimates Amidst Limited Revenue Disclosure BKR Q1 2026 Earnings EPS Surges Past Estimates by 16 Yet Stock Slides 53 Maplebear Inc CART Q1 2026 Earnings Earnings Miss Expectations Amid Quiet Revenue Disclosures IMA Q1 2026 Earnings Missed EPS Estimates Amid Continued Pipeline Development Manhattan Bridge Capital LOAN Holds Steady Near MidRange Despite Low Volume Zions Bancorporation ZION Holds Steady Amid Modest Pullback Key Levels in Focus Immersion Corporation IMMR Shows Modest Uptick Amid Tight Trading Range Principal Real Estate Income Fund PGZ Holds Steady Near Support After Minimal Gain WF International WXM Surges 6 Nearing Resistance at 051 Amid Renewed Buying Interest Borosil Glass Works Surges Over 200 in a Year on Strong Operational Performance ArrowMark Financial Corp BANX Q4 2022 Earnings EPS Misses Estimates by 196 Stock Declines Gen Digital Contingent Value Rights GENVR Extend Gains at 156 Key Levels in Focus HWBK Q1 2026 Earnings Solid EPS Performance Amidst Cautious Market Reception KRO Q1 2026 Earnings EPS Surprises Higher Despite Loss Stock Rises 206 DRTS Q1 2026 Earnings WiderthanExpected Loss as PreRevenue Company Continues Clinical Development NE Q1 2026 Earnings EPS Beats by 301 on Robust Operational Performance SUI Q1 2026 Earnings Misses EPS Estimates with Surprise Loss COST Q1 2026 Earnings EPS Misses Estimates as Membership Model Faces Margin Pressure C4 Therapeutics Q1 2026 Earnings Narrower Loss Surprises as Biotech Advances Pipeline